In Vivo Manufacturing: When The Body Becomes The Bioreactor

By Katie Perry, Senior Marketing Writer

Biologic innovation has transformed how we treat disease, but the way these therapies are made and delivered is increasingly at odds with their promise. From monoclonal antibodies to cell and gene therapies, today’s manufacturing models are complex, costly, and difficult to scale, leaving many patients without access to treatments that could change or save their lives. Even when therapies are available, administration burdens, side effects, and inconsistent efficacy limit their real-world impact. Meanwhile, promising new protein formats capable of tackling previously unreachable targets struggle to overcome stability and delivery challenges. This tension between scientific breakthrough and practical reality raises a critical question for the industry: can we rethink how advanced medicines are manufactured and delivered to expand access, improve patient experience, and unlock entirely new therapeutic possibilities?

Access the full article to explore what it could take to remove manufacturing as the bottleneck.